Close Menu

aneuploidy

First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.

Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.

The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.

Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.

Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2018.

The company is withdrawing its previous financial guidance for 2020, saying that it cannot predict the extent or duration of the impact of the COVID-19 pandemic.

AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.

Earlier this month, the company started accepting clinical samples at its CLIA/CAP laboratory in Pittsburgh and an affiliate laboratory in Malaysia.

Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.

Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.

Pages